PD-1 blockade induces responses by inhibiting adaptive immune resistance is a research paper published in Nature (2014). On theSindex it has a DataRank of 1.3. It has been cited 6,579 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
1.3
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institutes of Health
Grant: 1K08AI091663-01A1
Nanopolymersomes for Transcutaneous Co-Delivery of Vaccine Antigens and Adjuvants
National Institutes of Health
Grant: 3P30CA016042-35S3
Cancer Center Support Grant
National Institutes of Health
Grant: 1P01CA168585-01A1
TARGETED COMBINATORIAL TREATMENT OF BRAF MELANOMAS
National Institutes of Health
Grant: 5UL1TR000124-04
UCLA Clinical and Translational Science Institute
National Institutes of Health
Grant: 1U54CA119347-01
NanoSystems Biology Cancer Center
National Institutes of Health
Grant: 1R01CA170689-01
Strategies for Distinguishing Success in Immunotherapy Treatments (PQ20)
FWCI
188.58
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Metastatic lymph node targeted CTLA4 blockade: a potent intervention for local and distant metastases with minimal ICI-induced pneumonia
Additional file 1 of Metastatic lymph node targeted CTLA4 blockade: a potent intervention for local and distant metastases with minimal ICI-induced pneumonia
Additional file 1 of YOD1 serves as a potential prognostic biomarker for pancreatic cancer
Additional file 1 of YOD1 serves as a potential prognostic biomarker for pancreatic cancer
Additional file 1 of The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors
Additional file 1 of The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors
Additional file 2 of Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients
Additional file 2 of Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients
Additional file 1 of Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients
Additional file 1 of Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients
Additional file 3 of Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients
Additional file 3 of Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients
Additional file 1 of Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect
Additional file 1 of Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect
Additional file 2 of Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect
Additional file 2 of Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect
Additional file 3 of Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect
Additional file 3 of Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect
Additional file 1 of 18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma
Additional file 1 of 18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma